A group of Indian scientists has taken a giant step to develop a potential therapy for kala azar by using tiny molecules present in the body. It is estimated that kala azar affects 350 million in 88 countries and drug resistance is a major challenge in treating it. Around 65 percent patients in India have stopped responding to sodium stibogluconate - the drug of choice for the life-threatening visceral leishmaniasis or kala azar, says Neeloo Singh, senior principal ...
Read More
No comments:
Post a Comment